Compare ARDX & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | IVA |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.3M | 796.1M |
| IPO Year | 2014 | 2020 |
| Metric | ARDX | IVA |
|---|---|---|
| Price | $3.24 | $3.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $12.90 | ★ $15.20 |
| AVG Volume (30 Days) | ★ 4.1M | 2.3M |
| Earning Date | 10-29-2026 | 09-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $19.98 | N/A |
| Revenue Next Year | $27.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.18 | $3.11 |
| 52 Week High | $8.40 | $7.98 |
| Indicator | ARDX | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 29.24 | 32.35 |
| Support Level | N/A | N/A |
| Resistance Level | $3.63 | $4.80 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 12.50 | 1.54 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.